RRoche Read More Roche’s Columvi combo gains EC approval for DLBCL2026-06-14 Roche has secured approval from the European Commission (EC) for Columvi (glofitamab) plus gemcitabine and oxaliplatin (GemOx) combo…
RRoche Read More Health Canada Approves Roche’s Columvi® (glofitamab) as the First Bispecific Antibody in Canada for Relapsed or Refractory Diffuse Large B-Cell Lymphoma after Initial Therapy2026-03-06 DLBCL is an aggressive cancer with a high risk of progression meaning urgent and effective treatments are needed…